Nintedanib
Nintedanib is a kinase inhibitor taken by mouth to treat idiopathic pulmonary fibrosis (IPF), other chronic fibrosing interstitial lung diseases with a progressive phenotype, and, in some products, to slow lung function decline in systemic sclerosis-associated interstitial lung disease.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 12 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Nintedanib (Ofev), on the market since about 2014 and available as a generic, is one of two main anti-scarring medicines for idiopathic pulmonary fibrosis (IPF) and other progressive scarring lung diseases, including scleroderma lung disease for some products; it blocks kinases, enzymes that signal scar tissue to form, slowing rather than reversing the damage. Side effects land mostly on the gut, with diarrhea the one most people notice, so start fluids and loperamide early as your doctor directs. The one thing to look for is liver trouble (dark urine, yellowing skin or eyes), which is why blood tests are scheduled often in the first three months.
Clinical pearls
- Swallow capsules whole with food about 12 hours apart, never opening or chewing them; skip missed doses instead of doubling.
- It can harm an unborn baby, so if pregnancy is possible, use highly effective birth control until three months after stopping.
- Diarrhea or vomiting can make the pill less reliable, so add another highly effective birth control method during those spells.
- Smoking and St. John's wort both lower nintedanib levels, so quit smoking before starting and skip that supplement.
Patient information guide A plain-language walkthrough of Nintedanib, written from its FDA label.
What Nintedanib is used for
▾
Nintedanib is used in adults for scarring lung diseases.
- Idiopathic pulmonary fibrosis (IPF): Ofev, nintedanib esylate capsules, and nintedanib capsules.
- Chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype: Ofev, nintedanib esylate capsules, and nintedanib capsules.
- Slowing the decline in lung function in systemic sclerosis-associated ILD (SSc-ILD): Ofev and nintedanib capsules (100 mg and 150 mg). This use is not listed for nintedanib esylate capsules.
How Nintedanib works
▾
Nintedanib is a kinase inhibitor. It blocks several growth-factor receptors, including PDGFR, FGFR and VEGFR. These send signals involved in fibrotic tissue remodeling (scar formation) in the lungs.
It attaches to the ATP-binding pocket of these kinases and shuts down their signals inside cells. It also blocks Lck, Lyn and Src kinases. How much these other actions help in lung disease is unknown.
Nintedanib dosage
▾
Nintedanib is a capsule taken by mouth twice a day, about 12 hours apart, with food. Your prescriber will set the dose, and it may be lowered if you have mild liver impairment or side effects.
- Swallow capsules whole with liquid.
- Do not chew, open or crush them. They taste bitter.
- If you touch the contents, wash your hands right away.
- If you miss a dose, skip it and take the next one at the usual time. Do not make it up.
- Do not exceed the maximum daily amount on your label.
Dosing details from the FDA-approved label
From the Nintedanib prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Recommended dosage (all patients)
- 150 mg taken orally twice daily administered approximately 12 hours apart
- Maximum: Do not exceed the recommended maximum daily dosage of 300 mg
- Taken with food; swallowed whole with liquid; do not chew, open or crush
- Mild hepatic impairment (Child Pugh A)
- 100 mg orally twice daily approximately 12 hours apart taken with food
- Taken with food
- Moderate or severe hepatic impairment
- Treatment with nintedanib capsules is not recommended
- Dosage modification due to adverse reactions
- Treatment may be resumed at the full dosage (150 mg twice daily), or at the reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage
- If 100 mg twice daily is not tolerated, discontinue treatment
- Dose reduction or temporary interruption until the adverse reaction resolves
- Elevated liver enzymes: AST or ALT greater than 3 times to less than 5 times the ULN without signs of liver damage
- Interrupt treatment or reduce to 100 mg twice daily
- Once liver enzymes return to baseline, may be reintroduced at 100 mg twice daily, then increased to 150 mg twice daily
- Discontinue if AST or ALT greater than 3 times ULN with signs or symptoms of liver injury, or greater than 5 times ULN
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION • Recommended dosage: 150 mg taken orally twice daily approximately 12 hours apart taken with food. ( 2.2 ) • Recommended dosage in patients with mild hepatic impairment (Child Pugh A): 100 mg taken orally twice daily approximately 12 hours apart taken with food. ( 2.3 , 8.6 ) • Consider temporary dose reduction to 100 mg, treatment interruption, or discontinuation for management of adverse reactions. ( 2.4 , 5.2 , 5.3 , 6 ) • Prior to treatment initiation, conduct liver function tests in all patients and a pregnancy test in females of reproductive potential. ( 2.1 , 5.2 , 5.4 ) 2.1 Testing Prior to Nintedanib Capsules Administration Conduct liver function tests in all patients and a pregnancy test in females of reproductive potential prior to initiating treatment with nintedanib capsules [see Warnings and Precautions ( 5.2 , 5.4 )]. 2.2 Recommended Dosage The recommended dosage of nintedanib capsules is 150 mg taken orally twice daily administered approximately 12 hours apart. Administration Information Nintedanib capsules should be taken with food [see Clinical Pharmacology ( 12.3 )] and swallowed whole with liquid. Nintedanib capsules should not be chewed because of a bitter taste. Nintedanib capsules should not be opened or crushed. If contact with the content of the capsule occurs, wash hands immediately and thoroughly. The effect of chewing or crushing of the capsule on the pharmacokinetics of nintedanib is not known. Information for Missed Dose If a dose of nintedanib capsules is missed, the next dose should be taken at the next scheduled time. Advise the patient to not make up for a missed dose. Do not exceed the recommended maximum daily dosage of 300 mg. 2.3 Recommended Dosage for Patients with Hepatic Impairment Mild Hepatic Impairment In patients with mild hepatic impairment (Child Pugh A), the recommended dosage of nintedanib capsules is 100 mg orally twice daily approximately 12 hours apart taken with food [see Use in Specific Populations ( 8.6 )] . Moderate or Severe Hepatic Impairment Treatment with nintedanib capsules is not recommended [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.6 )] .
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Nintedanib side effects
▾
The most common side effects are mostly digestive.
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Abdominal pain
- Liver enzyme elevation (found on blood tests)
- Decreased appetite
- Weight loss
- Headache
- High blood pressure
When to get medical help
- Call your doctor if you have fatigue, loss of appetite, pain in the upper right belly, dark urine or yellowing of the skin or eyes. These can be signs of liver injury.
- Call your doctor if diarrhea, nausea or vomiting is severe or does not improve with treatment.
- Get emergency help for signs of a heart attack, such as chest pain.
- Report any unusual or serious bleeding.
- Get urgent help for severe belly pain, which can be a sign of a tear in the stomach or bowel (gastrointestinal perforation).
- Tell your doctor if you become pregnant or think you might be.
Nintedanib warnings and precautions
▾
- Liver injury: Enzyme rises and drug-induced liver injury, including fatal cases, have been reported. Most happen in the first three months. Low body weight (under 65 kg), Asian ancestry, female sex and older age may raise the risk of liver enzyme elevations.
- Digestive effects: Diarrhea, nausea and vomiting need early treatment. Severe cases that persist may require stopping.
- Pregnancy harm: It can cause fetal harm.
- Heart attack and clots in arteries: Use caution if you have higher cardiovascular risk, including coronary artery disease.
- Bleeding: It may raise bleeding risk.
- Gastrointestinal perforation: Be careful after recent abdominal surgery, with diverticular disease, or with corticosteroids or NSAIDs.
- Proteinuria: Nephrotic range proteinuria (large amounts of protein in the urine) has been reported.
Nintedanib interactions
▾
Some medicines change nintedanib levels or add to its risks.
- P-gp and CYP3A4 inhibitors (such as ketoconazole, erythromycin): can raise nintedanib levels, so you may need closer monitoring.
- P-gp and CYP3A4 inducers (such as rifampicin, carbamazepine, phenytoin, St. John's wort): can lower levels, so avoid them.
- Full-dose blood thinners: bleeding risk may rise.
- Oral hormonal contraceptives: vomiting or diarrhea may reduce how well they work.
- Pirfenidone and bosentan: no change in nintedanib exposure was seen.
Interactions listed in the FDA-approved label
From the Nintedanib prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- P-gp and CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): May increase exposure to nintedanib; ketoconazole increased exposure by 60%. Monitor patients closely for tolerability; management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy.
- P-gp and CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, St. John's wort): May decrease exposure to nintedanib; rifampicin decreased exposure by 50%. Concomitant use should be avoided.
- Anticoagulants: Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. Monitor patients on full anticoagulation therapy closely for bleeding and adjust anticoagulation treatment as necessary.
- Pirfenidone: Coadministration did not alter the exposure of either agent. No dose adjustment is necessary during concomitant administration.
- Bosentan: Coadministration did not alter the pharmacokinetics of nintedanib.
Read the label’s full interactions text
7 DRUG INTERACTIONS • Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. Monitor patients closely for tolerability of nintedanib capsules. ( 7.1 ) 7.1 P-glycoprotein (P-gp) and CYP3A4 Inhibitors and Inducers Nintedanib is a substrate of P-gp and, to a minor extent, CYP3A4 [see Clinical Pharmacology ( 12.3 )] . Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of P-gp and CYP3A4 inhibitors (e.g., erythromycin) with nintedanib capsules may increase exposure to nintedanib [see Clinical Pharmacology ( 12.3 )] . In such cases, patients should be monitored closely for tolerability of nintedanib capsules. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with nintedanib capsules [see Dosage and Administration ( 2.4 )] . Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e.g., carbamazepine, phenytoin, and St. John's wort) with nintedanib capsules should be avoided as these drugs may decrease exposure to nintedanib [see Clinical Pharmacology ( 12.3 )]. 7.2 Anticoagulants Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. Monitor patients on full anticoagulation therapy closely for bleeding and adjust anticoagulation treatment as necessary [see Warnings and Precautions ( 5.6 )]. 7.3 Pirfenidone In a multiple-dose study conducted to assess the pharmacokinetic effects of concomitant treatment with nintedanib and pirfenidone, the coadministration of nintedanib with pirfenidone did not alter the exposure of either agent [see Clinical Pharmacology ( 12.3 )] . Therefore, no dose adjustment is necessary during concomitant administration of nintedanib with pirfenidone.
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Nintedanib
▾
- Liver disease: not recommended for moderate or severe impairment. Mild impairment needs a reduced dose.
- Pregnancy: a pregnancy test is done first. Use highly effective contraception during treatment and for at least 3 months after.
- Breastfeeding: not recommended.
- Heart disease, bleeding risk, recent abdominal surgery or diverticular disease: tell your prescriber.
- Kidney disease: no starting-dose change for mild to moderate impairment. Not studied in severe or end-stage kidney disease.
- Smokers: smoking lowers drug levels, so you are encouraged to stop.
- Children: safety and effectiveness have not been established.
- Older adults: no overall differences were seen, but some may be more sensitive.
Nintedanib overdose
▾
In trials, people who took more than the recommended amount had side effects consistent with the known profile, and they recovered. If an overdose happens, treatment is interrupted and supportive care is given as needed.
What Nintedanib does in the body
▾
In a study in people with renal cell cancer, nintedanib did not lengthen the QTcF interval, a measure of the heart's electrical rhythm. This was true for a single dose and for repeated twice-daily dosing over 15 days.
How your body processes Nintedanib
▾
Nintedanib reaches peak blood levels about 2 to 4 hours after a dose taken with food. Only a small share is absorbed, and food raises exposure by about 20%. Its effective half-life in IPF is about 9.5 hours, and steady levels are reached within a week.
It is mainly broken down by esterase enzymes, with a small role for CYP3A4. Most of it leaves through stool and bile, and very little leaves through the kidneys.
How to store Nintedanib
▾
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) . Protect from exposure to high humidity and avoid excessive heat.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Nintedanib
285 supplements and herbal products have documented interactions with Nintedanib in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 5
- Moderate · 240
- Minor · 40
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Nintedanib: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Nintedanib — the kind of thing our pharmacy team would talk through with you at the counter.
What is nintedanib used for?
▾
How should I take my capsules?
▾
What side effects should I expect?
▾
Why do I need blood tests?
▾
Is it safe during pregnancy?
▾
Do I need to avoid any other medicines or smoking?
▾
Is Nintedanib available over the counter?
▾
When was Nintedanib first available?
▾
Who makes Nintedanib?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Nintedanib on HelloPharmacist
Nintedanib forms and strengths (how it comes)
Nintedanib is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Capsule
How this form is used
- Ofev is indicated for IPF, progressive chronic fibrosing ILDs, and SSc-ILD.
- Nintedanib esylate capsules are indicated for IPF and progressive chronic fibrosing ILDs.
- Nintedanib capsules (100 mg and 150 mg) are indicated for IPF, progressive chronic fibrosing ILDs, and SSc-ILD.
- Ofev capsules are taken by mouth about 12 hours apart with food and swallowed whole with liquid.
- Ofev capsules should not be chewed, opened or crushed. Wash hands right away if you touch the contents.
- Nintedanib capsules (100 mg and 150 mg) follow the same rules: with food, swallowed whole, and not chewed, opened or crushed.
- For a missed dose of nintedanib esylate capsules, skip it and take the next dose at the regular time.
Nintedanib on the U.S. market: products, makers and brands
How Nintedanib appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
12 companies list 24 Nintedanib product records with the FDA, mostly as capsule; the earliest marketing or approval year on record is 2014. Brand names on the directory include Ofev, Nintedanib esylate; the rest are generics.
Also listed with the FDA, not a patient dose form: Powder (17) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Nintedanib is used (Medicaid data)
A general measure of how commonly Nintedanib is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Nintedanib is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Nintedanib prescribed? Of the 1,601 medications we measure, Nintedanib ranks #981 by Medicaid prescriptions — more than 39% of them.
Utilization by Nintedanib product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
nintedanib 150 MG Oral Capsule Most dispensed
Summed across the 1 of 11 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1592750
nintedanib 100 MG Oral Capsule
Summed across the 1 of 11 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1592742
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Nintedanib, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 2 of 22 listed Nintedanib NDCs with Medicaid activity.
Compare Nintedanib products
A representative set of FDA-listed product records for Nintedanib — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Capsule | ||||
| 100 mg | Oral | Apotex Corp. | ANDA | View NDC → |
| 150 mg | Oral | Apotex Corp. | ANDA | View NDC → |
| 100 mg | Oral | AvKARE | ANDA | View NDC → |
| 150 mg | Oral | AvKARE | ANDA | View NDC → |
| 100 mg | Oral | Boehringer Ingelheim Pharmaceuticals, Inc. | NDA | View NDC → |
| 150 mg | Oral | Boehringer Ingelheim Pharmaceuticals, Inc. | NDA | View NDC → |
| 100 mg | Oral | Cipla USA Inc. | ANDA | View NDC → |
| 150 mg | Oral | Cipla USA Inc. | ANDA | View NDC → |
| 100 mg | Oral | Dr. Reddy's Laboratories Inc. | ANDA | View NDC → |
| 150 mg | Oral | Dr. Reddy's Laboratories Inc. | ANDA | View NDC → |
| 100 mg | Oral | Edenbridge Pharmaceuticals LLC. | ANDA | View NDC → |
| 150 mg | Oral | Edenbridge Pharmaceuticals LLC. | ANDA | View NDC → |
| 100 mg | Oral | Epic Pharma Llc | ANDA | View NDC → |
| 150 mg | Oral | Epic Pharma Llc | ANDA | View NDC → |
| 100 mg | Oral | Exelan Pharmaceuticals Inc. | ANDA | View NDC → |
| 150 mg | Oral | Exelan Pharmaceuticals Inc. | ANDA | View NDC → |
| 100 mg | Oral | Glenmark Pharmaceuticals Inc., USA | ANDA | View NDC → |
| 150 mg | Oral | Glenmark Pharmaceuticals Inc., USA | ANDA | View NDC → |
| 100 mg | Oral | Golden State Medical Supply, Inc. | ANDA | View NDC → |
| 150 mg | Oral | Golden State Medical Supply, Inc. | ANDA | View NDC → |
| 100 mg | Oral | Macleods Pharmaceuticals Limited | ANDA | View NDC → |
| 150 mg | Oral | Macleods Pharmaceuticals Limited | ANDA | View NDC → |
| 100 mg | Oral | Sandoz Inc | ANDA | View NDC → |
| 150 mg | Oral | Sandoz Inc | ANDA | View NDC → |
Showing 24 of 24 products — FDA National Drug Code Directory. See every product, package size and price: browse all 24 Nintedanib NDCs →
Nintedanib side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Nintedanib — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Nintedanib in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Nintedanib FDA approval history
How Nintedanib went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Nintedanib recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Nintedanib recalls since July 2021.
✅No Nintedanib recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 1592737 1 dose form · 2 strengths
-
Dose form (SCDF) Oral Capsule RxCUI 1592741In current FDA listings
Look up RxCUI 1592737 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Nintedanib supply and shortage status
Whether Nintedanib is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Nintedanib brand names
Nintedanib is sold under 2 brand names in the FDA directory — Ofev, Nintedanib esylate. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Nintedanib: manufacturers and labelers
12 companies list Nintedanib products with the FDA. By number of product records, the largest are Apotex Corp., AvKARE, Boehringer Ingelheim Pharmaceuticals, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Nintedanib drug class (RxNorm)
Nintedanib belongs to the Kinase Inhibitor class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Nintedanib page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Boehringer Ingelheim Pharmaceuticals, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →